Hyloris Announces Extension of Footprint of Maxigesic® IV into South America
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has extended its existing license and distribution agreement with Pharma Bavaria International for the commercialisation of Maxigesic IV, a novel, patented, non-opioid treatment for post-operative pain, in South America. The extended collaboration further builds on the agreement signed with Pharma Bavaria in February 2020 for ...
Source: biospace.com